secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008443
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio enters retention agreements with senior management amid strategic review
--------------------------------------------------------------------------------

- Retention agreements cover CEO, CFO, and other senior executives, providing lump sum cash equal to 50% of annual base salary upon qualifying termination or Feb 22, 2024.
- 50% acceleration of unvested equity awards granted in 2023 on qualifying termination after June 30, 2023.
- Stock option exercise period extended to 12 months post-termination or original expiry.
- Strategic alternatives process is ongoing; retention agreements designed to retain key talent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/0000950170-23-008443-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023008443/grph-20230310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008443

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer